L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each)
Lung Cancer
Explore 299 assets in Lung Cancer →Floatz Rating
CC47/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
protein_peptide
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
36Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05632809CT.gov REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) (this asset) | M.D. Anderson Cancer Center | P2 | CC · 47 |
| Cis-Diamminedichloroplatinum Ii | University of Vermont | P4 | BB |
| Carboplatin | SystImmune Inc. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Etoposide | SystImmune Inc. | P3 | BB |
| Nivolumab | University of Chicago | P4 | BB |
| Propofol | Kaohsiung Medical University Chung-Ho Memorial Hospital | P4 | BB |
| Vinorelbine Ditartrate | Alliance for Clinical Trials in Oncology | P3 | BB |
| Vinblastine | Intensity Therapeutics, Inc. | P3 | BB |
+42 more in the Lung Cancer cohort
Other indications for L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Non-Hodgkin Lymphoma | — | P2/3 | CCC · 53 |
| Relapsed/Refractory Diffuse Large B-Cell Lymphoma | — | P2/3 | CCC · 53 |
| Indolent B-Cell Non-Hodgkin Lymphoma | — | P1 | CC · 44 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. L-Methionyl-Interleukin 15 (Human, Non-Glycosylated), Produced In Escherichia Coli, Substituted On An Average Of One Site Among N2 Of Met1 And/Or N6 Of Lysyl Residues With 4-(.Alpha.-Methylpoly(Oxyethylene)-.Omega.-Oxy)Butanoyl Groups (~40 Kda Each) in Lung Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/l-methionyl-interleukin-15-human-non-glycosylated-produced-in-escherichia-coli-substituted-on-an-average-of-one-site-among-n2-of-met1-andor-n6-of-lysyl-residues-with-4-alpha-methylpolyoxyethylene-omega-oxybutanoyl-groups-40-kda-each-lung-cancer
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →